A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype
MD Anderson Study Status
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Glioma, Recurrent Malignant Glioma
John de Groot
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.